We seek to provide them with an excellent education and countless opportunities for development; then we watch them go on to successful and meaningful careers — as pharmacists, scientists, professors, public health officials, policymakers and much more.

We also take pride in the ways our students and faculty are responding to pressing needs in public health and health care. We are made up of an impassioned community of people working to improve the health and well-being of individuals and communities. This 2013 issue of “Excellence at the School of Pharmacy” is a testament to that.

Within these pages, you will find a snapshot of the work our students, faculty, alumni and volunteers are doing regionally and globally to improve health, health care and outcomes. On Page 3, for example, you will note the impressive amount of research funds our faculty members secured — for studies focused on areas including vaccine creation, drug interactions, obstetric-fetal pharmacology and comparative effectiveness research. Starting on Page 4, you can read about some students and faculty members who are having an impact — from a professor known for inspiring students in the classroom and the clinic to a graduate student helping surgeons in Tanzania improve surgical outcomes. On Page 10, we pay tribute to our generous donors and volunteers — without whom, we could not make the mark that we do.

You may notice that much of the work highlighted in this report is focused on finding safer, more-effective medicines and treatments. Part of our core mission is to help ensure the safe, rational and cost-effective use of medicines and medical products in human populations.

What a worthwhile goal this is. Better treatments lead to improved health outcomes. And that can open doors to a world of better health.

Thank you for your interest in and support of our School.

Sincerely,

Thomas A. Baillie, PhD, DSc

DEAN, UW SCHOOL OF PHARMACY
By the Numbers

3 The UW’s 2012 global ranking in clinical medicine and pharmacy by the Center for World-Class Universities

10 Our U.S. News & World Report 2012 ranking among schools of pharmacy

466 Currently enrolled students (364 PharmD, 59 PhD, 43 MS)

42 Full-time equivalent faculty members

500+ Clinical and affiliate faculty members

82 Percentage of PharmD graduates in 2012 who stayed in Washington to practice pharmacy

$17.5 million* Overall research funding secured

$34.6 million* Revenue

*Figures are from fiscal year 2012 (July 1, 2011-June 30, 2012)

Our Stellar Programs

DEGREES:
- Doctor of Pharmacy (PharmD)
- Master of Science (MS) in Biomedical Regulatory Affairs, Pharmaceutical Outcomes Research & Policy Program (PORPP)
- Doctor of Philosophy (PhD) in Medicinal Chemistry, Pharmaceutics, PORPP
- Concurrent: PharmD/PhD, PharmD/MS, PharmD/Master of Clinical Health Services

CERTIFICATES:
- Biomedical Regulatory Affairs
- Clinical Trials
- Comparative Effectiveness Research
- Health Economics & Outcomes Research
- Plein Certificate in Geriatric Pharmacy

Revenue

1% ENDOWMENT RETURN
2% SALES & SERVICES
3% RESEARCH COST RECOVERY
3% GIFTS
11% STATE FUNDS
13% OUTPATIENT PHARMACY
13% TUITION
51% GRANTS & CONTRACTS
<table>
<thead>
<tr>
<th>Abbreviated Project Title</th>
<th>Funding Agency</th>
<th>Direct Cost Fiscal Year 2012</th>
<th>PI</th>
<th>Multiyear Total, if Applicable*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pharm Optimization</td>
<td>NIH</td>
<td>$501,734</td>
<td>Anderson</td>
<td>$2,594,290</td>
</tr>
<tr>
<td>PGP Mechs</td>
<td>NIH</td>
<td>$219,000</td>
<td>Atkins</td>
<td>$880,685</td>
</tr>
<tr>
<td>LSDF BioE Center</td>
<td>WA Life Sciences Discovery Fund</td>
<td>$258,028</td>
<td>Atkins and</td>
<td>$980,778</td>
</tr>
<tr>
<td>Various Projects</td>
<td>Fred Hutchinson Cancer Research Center (FHCRC)</td>
<td>$33,469</td>
<td>Blough</td>
<td></td>
</tr>
<tr>
<td>HIV Env Trimer Spikes</td>
<td>NIH</td>
<td>$160,232</td>
<td>Catalano</td>
<td>$273,750</td>
</tr>
<tr>
<td>Lambda Capsid</td>
<td>National Science Foundation</td>
<td>$194,382</td>
<td>Catalano</td>
<td>$717,700</td>
</tr>
<tr>
<td>Viral DNA</td>
<td>NIH (U Cal San Diego subcontract)</td>
<td>$189,706</td>
<td>Catalano</td>
<td>$348,161</td>
</tr>
<tr>
<td>Andrews F32 Fellowship</td>
<td>NIH</td>
<td>$53,942</td>
<td>Catalano</td>
<td>$152,874</td>
</tr>
<tr>
<td>CERTN EDM Paper</td>
<td>AcademyHealth/AHRQ - ARRA</td>
<td>$7,500</td>
<td>Devine</td>
<td>$134,939</td>
</tr>
<tr>
<td>Fellowship</td>
<td>Allergan Inc.</td>
<td>$75,046</td>
<td>Devine</td>
<td></td>
</tr>
<tr>
<td>Comparative Eflec Rsch</td>
<td>PhRMA Foundation</td>
<td>$125,000</td>
<td>Garrison</td>
<td>$250,000</td>
</tr>
<tr>
<td>Pfizer Fellowship 3</td>
<td>Pfizer Inc.</td>
<td>$115,736</td>
<td>Garrison</td>
<td>$223,521</td>
</tr>
<tr>
<td>Bedalov Biomarkers Sub</td>
<td>NIH (FHCRC subcontract)</td>
<td>$8,123</td>
<td>Goodlett</td>
<td>$93,491</td>
</tr>
<tr>
<td>Artemisinin Compounds</td>
<td>WA Life Sciences Discovery Fund</td>
<td>$87,883</td>
<td>Goodlett</td>
<td>$258,527</td>
</tr>
<tr>
<td>g2AMPK</td>
<td>NIH</td>
<td>$34,102</td>
<td>Goodlett</td>
<td>$183,787</td>
</tr>
<tr>
<td>Morrisson P30 (Core B)</td>
<td>NIH</td>
<td>$175,846</td>
<td>Goodlett</td>
<td>$688,567</td>
</tr>
<tr>
<td>NW/RCE (RCE CORE D Y9)</td>
<td>NIH</td>
<td>$103,855</td>
<td>Goodlett</td>
<td>$519,773</td>
</tr>
<tr>
<td>Anticholinergic Med</td>
<td>Group Health Research Institute</td>
<td>$18,807</td>
<td>Gray</td>
<td>$93,491</td>
</tr>
<tr>
<td>UW-Obstetric Fetal Pharmacology R1</td>
<td>NIH NICHD</td>
<td>$515,550</td>
<td>Hebert</td>
<td>$3,250,000</td>
</tr>
<tr>
<td>pH-CD4-DSS</td>
<td>NIH</td>
<td>$586,292</td>
<td>Ho</td>
<td>$2,226,630</td>
</tr>
<tr>
<td>MIP HIV</td>
<td>NIH NIAID (U Utah subcontract)</td>
<td>$204,590</td>
<td>Ho</td>
<td>$1,061,619</td>
</tr>
<tr>
<td>Oral HIV vaccines</td>
<td>NIH</td>
<td>$277,789</td>
<td>Hu</td>
<td>$2,032,927</td>
</tr>
<tr>
<td>HIV-1 Drug Resistance</td>
<td>NIH NIAID (U Pittsburgh subcontract)</td>
<td>$181,563</td>
<td>Hu</td>
<td>$393,620</td>
</tr>
<tr>
<td>Pinter HIV/RAD Prj 3</td>
<td>NIH PHRI (U of Med &amp; Dentistry of NJ subcontract)</td>
<td>$389,050</td>
<td>Hu</td>
<td>$2,307,180</td>
</tr>
<tr>
<td>Hu-IPS st-HIV-1</td>
<td>Institut Pasteur of Shanghai-Chinese Acad Sciences</td>
<td>$143,768</td>
<td>Hu</td>
<td></td>
</tr>
<tr>
<td>Modulation of receptor</td>
<td>NIH NIAID (U Mass Medical School subcontract)</td>
<td>$518,457</td>
<td>Hu</td>
<td>$2,054,979</td>
</tr>
<tr>
<td>Clade C Core</td>
<td>NIH (Dana-Farber Cancer Institute subcontract)</td>
<td>$120,652</td>
<td>Hu</td>
<td>$1,069,773</td>
</tr>
<tr>
<td>Core A – NHP Model</td>
<td>NIAID (FHCRC subcontract)</td>
<td>$587,986</td>
<td>Hu</td>
<td>$3,030,628</td>
</tr>
<tr>
<td>Unmasking HIV Epitopes</td>
<td>Bill &amp; Melinda Gates Foundation</td>
<td>$5,175,945</td>
<td>Hu</td>
<td>$6,269,066</td>
</tr>
<tr>
<td>Xenobiotics</td>
<td>NIH</td>
<td>$186,219</td>
<td>Isoherranen</td>
<td>$933,664</td>
</tr>
<tr>
<td>Flu Fusion</td>
<td>NIH</td>
<td>$190,000</td>
<td>Lee</td>
<td>$950,000</td>
</tr>
<tr>
<td>Structure of HIV Env</td>
<td>NIH CFAR (U Alabama Birmingham subcontract)</td>
<td>$150,000</td>
<td>Lee</td>
<td>$207,789</td>
</tr>
<tr>
<td>Crucell Assays</td>
<td>Crucell Holland B.V.</td>
<td>$6,800</td>
<td>Lee</td>
<td></td>
</tr>
<tr>
<td>Guttmann F32 Fellowship</td>
<td>NIH</td>
<td>$49,214</td>
<td>Lee</td>
<td>$101,404</td>
</tr>
<tr>
<td>Pediatric CYP2D6</td>
<td>NIH (Children's Mercy Hosp, Kansas City subcontract)</td>
<td>$160,066</td>
<td>Lin</td>
<td>$524,287</td>
</tr>
<tr>
<td>Pharmacogenetics</td>
<td>NIH</td>
<td>$250,521</td>
<td>McCune</td>
<td>$501,543</td>
</tr>
<tr>
<td>Staff assignment</td>
<td>FHCRC</td>
<td>$24,416</td>
<td>McCune</td>
<td></td>
</tr>
<tr>
<td>UNCF/Merck – Hardy</td>
<td>United Negro College Fund</td>
<td>$90,000</td>
<td>Nelson</td>
<td></td>
</tr>
<tr>
<td>Plankton</td>
<td>NSF (Georgia Inst of Tech subcontract)</td>
<td>$31,495</td>
<td>Nunn</td>
<td>$94,511</td>
</tr>
<tr>
<td>HSR and D Project – VA</td>
<td>US Dept of Veterans Affairs</td>
<td>$11,700</td>
<td>Odegard</td>
<td></td>
</tr>
<tr>
<td>Drug Metabolism Training Grant</td>
<td>NIH</td>
<td>$566,295</td>
<td>Rettie</td>
<td>$2,828,769</td>
</tr>
<tr>
<td>Drug Interactions</td>
<td>NIH</td>
<td>$937,696</td>
<td>Rettie</td>
<td>$4,672,107</td>
</tr>
<tr>
<td>Bastyr/UW Oncomycology</td>
<td>NIH</td>
<td>$18,159</td>
<td>Shen</td>
<td>$46,159</td>
</tr>
<tr>
<td>PCOR K12</td>
<td>NIH/AHRQ</td>
<td>$417,820</td>
<td>Sullivan</td>
<td>$1,160,883</td>
</tr>
<tr>
<td>Variations in Health</td>
<td>Merck and Co. Inc.</td>
<td>$148,521</td>
<td>Sullivan</td>
<td></td>
</tr>
<tr>
<td>Pharmacogenetics</td>
<td>NIH/NIGMS</td>
<td>$2,307,604</td>
<td>Thummel</td>
<td>$8,053,777</td>
</tr>
<tr>
<td>Role of CYP212</td>
<td>NIH</td>
<td>$222,750</td>
<td>Totah</td>
<td>$1,118,250</td>
</tr>
<tr>
<td>UW Research Affil Prg Transporters</td>
<td>AstraZeneca LP/Genentech Inc./Merck</td>
<td>$240,000</td>
<td>Unadkat</td>
<td></td>
</tr>
<tr>
<td>CANCERGEN Y2</td>
<td>NIH (FHCRC subcontract) – ARRA</td>
<td>$351,881</td>
<td>Veenstra</td>
<td></td>
</tr>
<tr>
<td>GHC SA 2</td>
<td>NIH/Group Health</td>
<td>$29,196</td>
<td>Veenstra</td>
<td></td>
</tr>
<tr>
<td><strong>TOTAL:</strong></td>
<td></td>
<td><strong>$17,454,386</strong></td>
<td></td>
<td><strong>$51,609,016</strong></td>
</tr>
</tbody>
</table>

*Multyear totals on subcontract grants are estimated based on current year funding.
Doug Black’s ability to connect with students has made him well-liked among PharmD students since he first joined the Department of Pharmacy in 1989. Black, who teaches classes in pharmacotherapeutics and infectious disease, is known for tailoring his lectures to meet each group’s needs and for his enthusiasm for his subject matter.

Like many of his faculty colleagues, Black also serves as a preceptor to future pharmacists. As part of the UW Medical Center’s Division of Infectious Diseases health care team, he mentors several pharmacy residents and PharmD students on rotation each year. Patients in this unit are facing diseases ranging from HIV/AIDS to rare infections that can have devastating symptoms. That so many students and residents finish Black’s rotation with a newfound interest in working in infectious disease units is a testament to his clinical skills.

One lesson he teaches his mentees is that it is essential to consider the specific needs and issues of each patient when determining the right combination of medications. There is no “one size fits all” in pharmacotherapy. Just as, for Black, there is no “one size fits all” in teaching. His personal approach is one of the reasons he has received the UW’s highest teaching honor — the Distinguished Teaching Award. And it’s just one of the reasons why the PharmD program is known for innovation in education.
ONE DEGREE, MANY OPTIONS FOR THE FUTURE

While he was a PharmD student, Zsolt Hepp placed nationally in two academic competitions. In 2009, he was on a student team that took grand prize in the National Community Pharmacists Association Pruitt-Schutte Business Plan Competition. In 2010, Hepp and his team placed second in the Academy of Managed Care Pharmacy’s Annual Pharmacy & Therapeutics (P&T) Competition.

As he prepared for these contests, Hepp gained a greater understanding of the complexity of the pharmacy profession and the health care system. His P&T research in particular piqued his interest. P&T focuses on formulary management — the process of approving drugs for safety and cost effectiveness and making recommendations for use and preparation. Hepp saw how much this information shapes health policy, and he decided to become involved in influencing patient outcomes at this level.

After graduating in June 2012, he took on two roles — as a pharmacist at Walgreens and an Allergan Fellow in our School’s Pharmaceutical Outcomes Research & Policy Program (PORPP). At Walgreens, Hepp is managing patients’ needs on an individual level. As a PORPP fellow, he is evaluating health-related outcomes for medications on a larger scale. At present, he is examining resource-use patterns in migraine patients using prophylactic medications.

When he enrolled at the UW, Hepp didn’t know he’d become interested in so many different aspects of patient care. But that’s what the School of Pharmacy is about — creating diverse opportunities and letting students like Hepp find their passion and thrive.

MEETING THE NEEDS OF OUR NATION’S SENIORS

PharmD candidate Laura Hart, ’14, spent three years volunteering at a long-term care center pharmacy prior to pharmacy school. While there, she saw firsthand the important role pharmacists play in improving the health of older adults. As someone close to her own grandparents, she loved working with this population of people.

Today, the third-generation UW pharmacy student contributes widely to the School’s efforts to advocate for older populations. She is president of the UW student chapter of the American Society of Consultant Pharmacists (ASCP) — a geriatric pharmacy organization. Her work with ASCP has included organizing and participating in medication reviews, fall-prevention programs and osteoporosis-prevention workshops.

Hart is pursuing the Plein Certificate in Geriatric Pharmacy, and she is a Plein Fellow in Geriatrics. As a fellow, she recently started a research project with UW Pharmacy Cares, the School’s consulting pharmacy program. She and faculty members Karan Dawson and Susan Lakey are working with two Era Living Retirement Community sites to look at medication-related problems and to assess resident, family and staff perceptions of consulting pharmacy services.

Hart is one of many UW PharmD students who are highly involved in outreach, research and leadership activities. What’s more, her fellow students are engaged in projects supporting many populations and public health issues. In the pharmacy field, after all, there are countless ways to make a difference. For Hart, this means a future career serving the complex health needs of a generation close to her heart.

For Zsolt Hepp, his PharmD degree helped him discover a newfound interest in evaluating health-related outcomes for medications.

Laura Hart, seen here at an osteoporosis-screening event, looks forward to a career helping improve the health of older generations.
Each year, 1.7 million people in the United States sustain a traumatic brain injury. Although numerous clinical studies have tried using single drug treatments for people with brain injuries, the results have been overwhelmingly disappointing. Gail Anderson, professor of pharmacy and adjunct professor of pharmaceutics and neurosurgery, is in search of a more successful treatment method.

Her current research, funded by a $2.5 million NIH grant, seeks to identify combinations of medications that could prevent long-term health issues for brain-injured patients. Some of these long-term issues include epilepsy and residual physical, cognitive, emotional and behavioral impairment.

Anderson knows that daily life can change significantly for patients diagnosed with epilepsy. With this in mind, she has been a patient advocate, community volunteer and professional advisory board member of the Epilepsy Foundation Northwest for more than 20 years. She also precepts pharmacy students at the UW Regional Epilepsy Center at Harborview Medical Center — helping them provide the best care possible to patients in the clinic and at the bedside.

A UW alumna (BS in pharmacy, MS in pharmacy practice, PhD in pharmaceutics), Anderson received the School’s 2010 Distinguished Alumna Award for her research, teaching and community involvement. It is one of many career honors she has received. While Anderson appreciates such accolades, what she especially appreciates is knowing that her research could one day help people seeking hope after surviving a traumatic injury.
ASSESSING SURGICAL OUTCOMES IN TANZANIA

Pharmaceutical Outcomes Research & Policy Program (PORPP) graduate student Amy Cizik spent last summer in Dar Es Salaam, Tanzania piloting a mobile phone application that enters surgical follow-up data. Cizik sought to determine whether surgeons at the Muhimbili Orthopaedic Institute could more easily enter patients’ post-surgery progress with a smart phone data and photo application than with traditional data entry methods.

Andy Stergachis, PORPP adjunct professor and UW professor of global health, guided Cizik in her proposal for funding and served as her project mentor. The funding came from the UW Thomas Francis, Jr., Global Health Fellowship Program. In addition, Cizik collaborated with SIGN Fracture Care International, a humanitarian organization that provides orthopaedic treatment to people in developing countries.

What Cizik ultimately discovered during her time in Tanzania was that few people who receive fracture care at the Institute actually return for follow-up. They don’t have the means to get back to the clinic to meet with a physician. Cizik, therefore, will continue working with SIGN to assess better methods for patient follow-up. Ultimately, she hopes to help SIGN track patients’ outcomes and to help SIGN’s patients worldwide get the appropriate follow-up care in their recovery process.

Cizik enrolled in PORPP because of its focus on improving health care decisions for patients and decision makers. With a background in public health and orthopaedics research, she wanted to research the clinical and economic effects of orthopaedic devices in patient populations.

In the future, she hopes to collaborate with orthopaedic surgeons to study cost and outcomes of orthopaedic interventions or to help surgeons in other countries conduct similar research. No matter how this takes shape, she will have an international network of support as an alumna of PORPP.
More than a decade ago, Professor of Pharmaceutics Jashvant Unadkat began studying how drug transporters affect the disposition, efficacy and toxicity of drugs used to treat diseases such as hepatitis C and AIDS. Transporters are membrane proteins that help the body absorb, distribute, metabolize and excrete drugs. Given the complexity of transporters, the variability of human genetics, and the sheer volume of transporters in the human body, the collective scientific knowledge about transporters has long contained many gaps. Unadkat seeks to change that.

In 2012, he launched the UW Research Affiliates Program on Transporters (UWRAPT), a partnership between the School of Pharmacy and AstraZeneca, Genentech and Merck. The UW Center for Commercialization and Office of Sponsored Programs helped make this undertaking possible.

Through UWRAPT, researchers from the four institutions are collaborating on nonproprietary research to enhance knowledge about the types and amount of transporters expressed in human tissues. This kind of academic-industry collaboration on nonexclusive research is rare. And it has exciting implications for other potential future partnerships that our School could launch.

Unadkat and UWRAPT lead scientist Bhagwat Prasad hope UWRAPT’s research will advance the collective knowledge about how the body processes medicines. They want to help scientists better predict the fate of new drugs early in development. In turn, this will help health care providers prevent drug interactions and understand how genetics affect the way individuals process medications.

“This kind of academic-industry collaboration on nonexclusive research is rare. And it has exciting implications for other potential future partnerships that our School could launch.”
A Continued Legacy of Innovation

Our School is continually finding ways to innovate education, research and outreach. In fact, we’re leading the way in these endeavors. The following are some of the new programs we have launched in the past five years alone:

- Analytical Biopharmacy Core, in partnership with the UW Department of Bioengineering
- Biomedical Regulatory Affairs Master of Science
- Certificate in Health Economics and Outcomes Research
- Graduate Certificate in Comparative Effectiveness Research
- Northwest-Alaska Pharmacogenomics Research Network, in partnership with several tribes, foundations and universities
- Pharmacological Sciences Summer Diversity Research Program
- UW Global Medicines, in partnership with the UW Department of Global Health
- UW Pharmacy Cares Consulting Pharmacy
- UW Research Affiliate Program on Transporters, in partnership with AstraZeneca, Genentech and Merck

OPENING DOORS FOR YOUNG RESEARCHERS AND SCIENTISTS

Professor of Medicinal Chemistry Carlos Enrique Catalano has devoted his career to understanding how viruses work — specifically how they put themselves together in an infected cell. Current studies in his lab focus on HIV and on bacteriophage lambda, a virus that looks and behaves like the herpes viruses. By enhancing scientific knowledge about the formation of these viruses, Catalano’s research could make it easier for researchers to design specific antiviral drugs and vaccines.

Catalano is also devoted to mentoring young people from diverse backgrounds. As faculty adviser to the award-winning UW chapter of the Society for the Advancement of Chicanos and Native Americans in Science, Catalano works with an enthusiastic group of undergraduate and graduate students engaged in scientific research. These students themselves have developed outreach programs for Latino and Native American high schoolers.

Like many other faculty members, he also offers undergraduates the chance to work in his lab. Students come to the Catalano Lab from programs such as the Amgen Scholars Program, the UW School of Pharmacy’s Pharmacological Sciences Summer Diversity Program, and the UW’s Post-Baccalaureate Research Education Program (PREP), funded by NIH. Catalano helped create the Diversity Program and he serves as co-PI for PREP.

Catalano enjoys trying to instill a love of science in young people. Who knows? One day, one of those young people might work on the cure for a virus studied in the Catalano Lab.
We are so grateful to our volunteers and donors for their time, energy and financial contributions. Their support is critical to our efforts to educate first-rate pharmacists, develop scientific leaders and serve the community. In these pages, we present the names of the companies and individuals that made gifts to our School at the Dean’s Club Level and above, and those that gave donations to student events in fiscal year 2012 (July 1, 2011 to June 30, 2012). We also present the names of our advisory board members from fiscal year 2012.

While these are our most prominent supporters, there are countless more individuals and companies working behind the scenes to support our students, faculty and School in so many ways. We are indebted to every single one of you.

Our Donors

CORPORATIONS AND FOUNDATIONS
$25,000+
Allergan Inc.
Amgen
Bayer AG
ERA Living
Bill & Melinda Gates Foundation
Genentech
Kelley-Ross Pharmacy
McKesson Corporation
Merck & Co. Inc.
Pfizer Inc.
PhRMA Foundation
Public Health Research Institute
United Negro College Fund

Rite Aid Corporation
Safeway District Management
The Bartell Drug Company
WA State Pharmacy Foundation
Walter & Hazel Hinman Fdtn.

LESS THAN $2,500
Abbott Fund
Albertson’s Inc.
Aqua Verde Cafe Paddle Club
Asia Gifts & Aquarium
Beal's Compounding Pharmacy
Bergman Luggage Company Inc.
Bioscrip Pharmacy
Bob Johnson’s Pharmacy
The Boeing Company
Bonck Family Trust
Bristol-Myers Squibb Foundation
Career Staff Rx
Central WA Hospital Pharmacy
Chinook Pharmacy Inc.
Columbia Valley Com. Health

A proud tradition continues:
Our School is once again ranked No. 1 among all UW schools in terms of percentage of alumni giving!

Newly Created School of Pharmacy Funds 2012
- Andjelkovic Connell Endowed Student Support Fund
- Doug Black Endowed Fund
- Higashi Family PORPP Endowed Student Fellowship Fund
- Kelley-Ross Faculty Fellowship
- Dennis Lam Memorial Fund
- Stergachis Family Endowed PORPP Directorship

$10,000 - $24,999
GlaxoSmithKline
The Kroger Co.
Walgreens

$2,500 - $9,999
AcademyHealth
American Pharmacists Association
Bi-Mart
CVS Caremark
Eli Lilly & Co. Foundation
GE Foundation
Genentech Inc.
John Wiley & Sons Inc.
Kelley-Ross Pharmacy Inc.
Lincoln Pharmacy
Morgan Stanley/SmithBarney

Com. Health Ctr. of Snohomish
Community Pharmacy Scotland
Dimitriou’s Jazz Alley
Dow AgroSciences LLC
Evergreen Hospital Med Ctr.
Evergreen Senior Health Specialist
Experience Music Project
Fdn. for Managed Care Pharmacy
Fred Meyer
Garage
Garfield Medical Square Pharmacy
Genelex
Greater Everett Community Fdtn.
Green Mountain Coffee Roasters
Harrison Medical Center
HealthPoint
Island Hospital Anacortes

continued on page 11
Remodeled Bracken Center Unveiled

In fall quarter 2012, the newly remodeled L.D. & Jim Bracken Pharmacy Learning Center, our PharmD student learning lab, opened! It features upgrades to the center’s integrated learning areas, which include a sterile products preparation room, patient-counseling areas and a retail space. In addition, the beautiful new lab now has advanced QS1 software and more advanced pharmacy learning technology.

This remodel was made possible by the Bracken Family, CVS Pharmacy, Kelley-Ross Pharmacy, McKesson Inc. and Walgreens.
Kevin Hiroo  
Rodney Ho & Lily Hwang-Ho  
Richard & Janet Hunter  
Al & Carollyn James  
Bradley Kerr & Caroline Lee  
Kevin Koch & Kathy Maloney  
Stephen & Kathy Kushner  
Mark Holodniy & RoseAnn Kushner  
Craig & Sally Kvam  
Michael & Tammy Lafferty  
Virginia Leland  
Donavon & Nicole McConn  
David Nelson  
Patrick & Missy O’Donnell  
Richard & Jane Ramsey  
Brian Seiki  
Kenneth & Peggy Thummel  
Chris & Gail Whitley  
Larry & Margaret Wienkers  
Donald & Arda Williams  
Bradley Wong  
Mingshe Zhu  

**DEAN’S CLUB**  
Kimberly Adkison  
Arnold & Gail Anderson  
Richard & Teresa Austin  
Ronald & Kathleen Beil  
Cynthia Bishop  
Kari & Adam Brothers  
Cindy Bueler  
Sonja Carlson & Bobby Kishore  
Judith & Barry Christensen  
Bonnie & Walter Davison  
James & Karan Dawson  
Beth Devine  
Leslie Dickmann  
Donald & Donna Dockter  
Donald & Anne Downing  
Gregory Edmiston & Debra Leith  
Jon Eisenberg & Soraya Madani  
William & Sharon Fassett  
Andrew & Claire Forster  
Vivian & Roel Ganiron  
Mark & Sissi Grillo  
Shuko Hara  
Thomas Hazlet  
Kirk Henne  
Nina Hill  
Vivian & Jeffrey Hiroo  
Peng Hsiang  
Shiu-Lok Hu  
Lorraine Humm  
Paul & Mary Kuehn  
Joseph & Yue Lam  
Sze Lau  
Rene & Beloria Levy  
Richard & Margaret Marshall  
Anne Mock  
Michael Mohutsky  
Kellie Nakamura  
David & Peggy Odegard  
Larry & Ellen Oliver  
Marla & Patrick Osinski  
Guy Padbury  
Ruth & Patrick Parker  
Kevin Pasquali  
Gregory & Gloria Pollock  
C. Rene & David Porubek

“Because of the support of people like you, I was able to achieve my dream and attend this university. I hope my experience at the UW will lead to opportunities that will help me contribute to a wide variety of populations in my career.”  
**PAIGE MATHEW, ’16, SCHOLARSHIP RECIPIENT**
Every effort has been made to represent the names of our donors at the Dean’s Club level and above in fiscal year 2012 accurately. We apologize for any errors or omissions. For a full list of donors to the School, visit sop.washington.edu and view the Fall 2012 alumni magazine, Dawg Scripts.

Our Board Members

CORPORATE ADVISORY BOARD
(Organizations with Member Representatives)
Abbott Laboratories
Allergan Inc.
Amgen Inc.
Astellas U.S. Inc.
AstraZeneca
Bayer Healthcare
Bend Research Inc.
Biogen Idec
Boehringer Ingelheim Pharmaceuticals
Bristol-Myers Squibb
Celgene Corporation
Covance
dwm Consulting LLC
Eli Lilly & Co.
En Vivo
GE Healthcare
Genentech Inc.
GlaxoSmithKline
Hoffman-La Roche
Ironwood Pharmaceuticals
Janssen Alzheimer Immunotherapy
Johnson & Johnson
Lilly Research Labs
McKesson Corp.
Medtronic
Merck
Mitsubishi Tanabe
Novartis
Omeros Corp.
Pfizer Inc.
Premera Blue Cross
Sanofi-Aventis
SAR Safety Assessment
Seattle Genetics
Takeda Pharmaceuticals International
Theravance Inc.
Vertex Pharmaceuticals

PHARMACY PRACTICE ADVISORY BOARD
Carol Carnahan, ‘80, Bartell Drug Co.
Collin Conway, ‘05, Group Health
Daiana Huyen, Walgreens
Al Linggi, ‘71, McKesson Corp.
Ryan Oftebro, ‘03, Kelley-Ross Pharmacy
Chuck Paulsen, Quality Food Centers
Jeff Rochon, ‘99, WSPA
Steve Singer, ‘81, Bellegrove Pharmacy
Shabir Somani, UW Medicine
Susan Teil Boyer, ‘72, American Society of Health-System Pharmacists
David West, ‘79, Swedish Hospital
Jennifer Wilson-Norton, ‘93, The Evergreen Clinic

PHARMACY ALUMNI ASSOCIATION BOARD OF DIRECTORS
President:
Jennifer Glasco, ‘09, The Polyclinic
Immediate Past-President:
Jenny Arnold, ‘06, Washington State Pharmacy Association (WSPA)
Past Presidents:
Suzanne Lee, ‘88, Northwest Hospital, and Ben Michaels, ‘97, St. Francis Hospital
Member at Large:
Judi Mar-Burbidge, ‘82, ‘00, Seattle Veterans Administration
Katterman Chair:
Don Downing, ‘75, UW School of Pharmacy
WSPA Liaison:
Jeff Rochon, ‘99, WSPA

At left is UW Professor of Epidemiology and Global Health and Adjunct Professor of Pharmacy Andy Stergachis. To his right are Stergachis Family Endowed PORPP Director and Professor Sean Sullivan, School of Pharmacy Distinguished Alumnus Award Recipient Ryan Hansen, PharmD, ‘03, PhD, ‘12, and Washington State Pharmacy Foundation President John Oftebro.
SELECTED PUBLICATIONS

This list includes a sampling of recent books, book chapters, articles and reviews in professional journals. It excludes letters, technical reports and conference presentations. School of Pharmacy authors (including current and recent faculty members, affiliate and adjunct faculty members, researchers, postdoctoral fellows, and students) are in bold.


**Chan LN.** To Hold (Enteral Feeding) or Not to Hold: That IS the Question; A Commentary and Tutorial. *Practical Gastroent* 2012.


**Downing D.** Inviting the pharmacist: a model for improved reproductive care access (Editorial). *Contraception* 2012.

**Endsley AN, Ho RJY.** Design and characterization of novel peptide coated lipid nanoparticles for specific anti-HIV drug delivery to HIV host cells. *AAPS J* 2012.


In the past few years, our faculty members have been interviewed for stories in the Associated Press, New York Times, Huffington Post, Seattle Times and Pacific Northwest Magazine, as well as for stories on KUOW radio and KOMO4 TV, among others.
“Part of our core mission is to help ensure the safe, rational and cost-effective use of medicines and medical products in human populations. What a worthwhile goal this is. Better treatments lead to improved health outcomes. And that can open doors to a world of better health.”

DEAN THOMAS BAILLIE

SCHOOL OF PHARMACY
UNIVERSITY OF WASHINGTON

Creating healthier lives. It’s the Washington Way.